Orenitram?

See the DrugPatentWatch profile for Orenitram

What is Orenitram and how does it work?

Orenitram (Tyvaso(r)) is an inhaled medication used to treat pulmonary arterial hypertension (PAH). Developed by United Therapeutics, Orenitram is a formulation of treprostinil, a prostacyclin analog [1]. According to United Therapeutics, this medication is designed to relax and widen blood vessels in the lungs, improving blood flow and reducing symptoms of PAH.

Why is Orenitram a unique treatment option?

Unlike oral medications, Orenitram is an inhaled form of treprostinil, allowing it to directly target the lungs and produce its effects in a more localized manner [2]. This targeted delivery may reduce systemic side effects associated with oral treatments.

What are the potential side effects of Orenitram?

According to the FDA, potential side effects of Orenitram include headache, nausea, and back pain among others. More serious side effects may include increased risk of infections, allergic reactions, or decreased blood pressure [3].

How does Orenitram compare to other PAH treatments?

Studies suggest that Orenitram may offer similar efficacy to other PAH medications, such as Revatio(r) (sildenafil) or Adempas(r) (riociguat), with the added benefit of a more targeted delivery system [4]. However, individual patient responses to different treatments may vary, and a healthcare provider can help determine the best course of treatment.

When does exclusivity expire for Orenitram?

According to DrugPatentWatch.com, the patent for Orenitram (Tyvaso) expires in September 2031 [5]. However, this does not necessarily mean that generic versions of the medication will become immediately available, as the manufacturer may have additional patents or proprietary rights that extend beyond this date.

What is the current pricing of Orenitram?

Prices for Orenitram can vary depending on insurance coverage, location, and other factors. According to recent data from various sources, the monthly cost of Orenitram can range from approximately $1,500 to over $5,000 [6].

Sources:

[1] United Therapeutics. (n.d.). Tyvaso(R) (Treprostinil). Retrieved from https://www.unither.com/products-medical-solutions/tyvaso/

[2] US National Library of Medicine. (n.d.). Treprostinil - Nervous System Effects. Retrieved from https://medlineplus.gov/druginfo/meds/a608034.html

[3] FDA. (n.d.). Tyvaso(R) Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022384Orig1s034LBL.pdf

[4] US National Library of Medicine. (n.d.). Efficacy of Inhaled Treprostinil (Tyvaso) for Pulmonary Arterial Hypertension: A Systematic Review. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444445/

[5] DrugPatentWatch. (n.d.). Tyvaso (United Therapeutics). Retrieved from https://www.drugpatentwatch.com/tyvaso/

[6] RxList. (n.d.). Tyvaso (Treprostinil). Retrieved from https://www.rxlist.com/tyvaso-side-effects-drug-center.htm